Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined with Fulvestrant and Angiogenesis Inhibitors in Advanced HR+/HER2- Breast Cancer
NCT06750848Phase 2Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in breast cancer. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06750848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750848.